TriangleAlectinib ± Radiosurgery (NCT05987644)
Alectinib ± Radiosurgery trial for ALK-Positive Lung Cancer With Brain Metastases (NCT05987644). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with ALK positive lung cancer that has spread to the brain, with few or no symptoms, who have not been treated yet.
The idea: alectinib is a twice daily pill that targets ALK and can reach the brain. The question is whether brain radiation can wait. In the phase 2 part, one group takes alectinib alone, and another gets stereotactic radiosurgery, a focused high dose of radiation, plus alectinib.
This phase 1 and 2 study plans 56 patients. At Ohio State University Comprehensive Cancer Center in Columbus, Joshua Palmer leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.